CVM · CEL SCI CORP
No longer meets the screen criteria as of 2026-07-15 — TTM revenue = $0. The page is kept because the daily page for the day the insider bought links here, and that purchase still happened.
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Cap structure and valuation
| Cap structure | |
|---|---|
| SP | $1.09 |
| SO | 8.5M |
| Options | 0.7M |
| Warrants | 0.0M |
| FD SO | 9.2M |
| MC | $10.1M |
| Cash | $1.9M |
| Total debt | $6.8M |
| EV | $15.0M |
| TTM Multiples | |
|---|---|
| EV / Revenue | — |
| EV / EBITDA | — |
| MC / Net Income | 0.4x |
| EV / FCF | — |
| MC / FCF | — |
| Ownership & coverage | |
|---|---|
| Institutional | 4.4% |
| Insiders | 6.3% |
| # Institutions | 45 |
| Analysts | 0 |
| Consensus | — |
| Avg target | — |
| Short % float | 1.6% |
| Days to cover | 0.69 |
MC = SP × FD SO. EV = MC + Debt − Cash. SP = previous yfinance close. Balance-sheet figures as of 2026-05-11. Multiples use TTM (sum of last 4 quarters); shown as "—" when the denominator is zero or negative, or when fewer than four quarters are reported — a partial sum is not a trailing twelve months. Ownership & coverage per Yahoo Finance as of 2026-07-13 — institutional % is 13F-based, so it can lag a quarter and exceed 100% on share-count timing. Short interest per FINRA bi-monthly reporting, as of 2026-06-29; the float denominator can be unreliable on tiny floats.
Financial statements
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| SG&A | 1.56 | 1.69 | 2.33 | 1.75 |
| R&D | 3.77 | 3.68 | 3.70 | 3.74 |
| Operating Income | (5.33) | (5.37) | (6.03) | (5.49) |
| Operating Income YoY % | 16.7% | 22.1% | 1.4% | 17.7% |
| EBITDA | — | (4.40) | (5.07) | (4.53) |
| Interest Expense | 0.12 | 0.09 | (0.13) | (0.17) |
| Other Income / (Expense) | 10.91 | 10.93 | 50.63 | (27.64) |
| Pretax Income | 5.47 | 5.47 | 44.72 | (32.96) |
| Net Income | 5.47 | 5.47 | 44.72 | (32.96) |
| Net Income to Common | (5.47) | (5.47) | (6.10) | (5.66) |
| Diluted EPS | $0.67 | $0.68 | $0.07 | -$1.36 |
| Diluted Avg Shares | 8.1 | 8.0 | — | 4.2 |
| LTM | 9/30/25 | 9/30/24 | 9/30/23 | 9/30/22 | |
|---|---|---|---|---|---|
| SG&A | 7.33 | 8.92 | 8.19 | 9.00 | 10.71 |
| R&D | 14.89 | 15.89 | 18.16 | 22.47 | 25.36 |
| Operating Income | (22.22) | (24.81) | (26.35) | (31.48) | (36.06) |
| Operating Income YoY % | 10.5% | 5.9% | 16.3% | 12.7% | — |
| EBITDA | — | (22.75) | (24.22) | (29.36) | (34.09) |
| Interest Expense | (0.10) | 0.65 | 0.75 | 0.68 | 1.08 |
| Other Income / (Expense) | 44.82 | 50.87 | 54.02 | — | — |
| Pretax Income | 22.70 | 25.41 | 26.92 | (32.19) | (36.70) |
| Net Income | 22.70 | 25.41 | 26.92 | (32.19) | (36.70) |
| Net Income to Common | (22.70) | (25.41) | (26.92) | (32.37) | (36.70) |
| Diluted EPS | $0.06 | $6.27 | $15.31 | -$0.73 | -$0.87 |
| Basic EPS | — | — | — | — | -$0.87 |
| Diluted Avg Shares | 8.1 | 4.1 | 1.8 | 44.5 | 43.1 |
| Basic Avg Shares | — | — | — | — | 43.1 |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Cash & Equivalents | 1.89 | 6.28 | 10.95 | 1.79 |
| Other Current Assets | 1.00 | 0.75 | 0.64 | 0.83 |
| Total Current Assets | 2.89 | 7.03 | 11.60 | 2.62 |
| Net PPE | 5.07 | 5.57 | 6.08 | 6.58 |
| Operating Lease ROU | 1.49 | 1.54 | 1.27 | 1.33 |
| Intangible Assets | 0.07 | 0.10 | 0.12 | 0.13 |
| Other Assets | 8.18 | 8.65 | 9.09 | 9.67 |
| Total Assets | 17.71 | 22.89 | 28.16 | 20.34 |
| Accounts Payable | 0.93 | 1.03 | 1.06 | 1.58 |
| Current Debt | — | — | 2.27 | — |
| Current Lease Liabilities | 0.20 | 0.17 | 0.17 | 0.19 |
| Other Current Liabilities | 3.68 | 3.84 | 1.63 | 3.85 |
| Total Current Liabilities | 4.81 | 5.04 | 5.13 | 5.62 |
| Long-term Debt | — | — | 5.68 | — |
| Long-term Lease Liabilities | 1.47 | 1.52 | 1.26 | 1.30 |
| Other Liabilities | 4.56 | 5.19 | — | 6.40 |
| Total Liabilities | 10.83 | 11.76 | 12.20 | 13.31 |
| Retained Earnings | (550.36) | (544.89) | (539.42) | (533.32) |
| Total Equity | 6.87 | 11.14 | 15.96 | 7.02 |
| LTM | 9/30/25 | 9/30/24 | 9/30/23 | 9/30/22 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.89 | 10.95 | 4.74 | 4.15 | 22.67 |
| Short-term Investments | — | — | — | — | 0.00 |
| Receivables | — | — | — | — | 0.00 |
| Inventory | — | — | 1.02 | 2.25 | 2.00 |
| Other Current Assets | 1.00 | 0.64 | — | 0.52 | 0.76 |
| Total Current Assets | 2.89 | 11.60 | 6.06 | 6.92 | 25.44 |
| Net PPE | 5.07 | 6.08 | 8.13 | 10.19 | 11.89 |
| Operating Lease ROU | 1.49 | 1.27 | 1.50 | 1.70 | 1.88 |
| Intangible Assets | 0.07 | 0.12 | 0.17 | 0.20 | 0.21 |
| Other Assets | 8.18 | 9.09 | 11.14 | 11.53 | 11.10 |
| Total Assets | 17.71 | 28.16 | 26.99 | 30.53 | 50.52 |
| Accounts Payable | 0.93 | 1.06 | 1.45 | 2.01 | 1.62 |
| Current Debt | — | 2.27 | — | — | — |
| Current Lease Liabilities | 0.20 | 0.17 | 0.23 | 0.20 | 0.17 |
| Other Current Liabilities | 3.68 | 1.63 | 2.94 | 3.38 | 2.87 |
| Total Current Liabilities | 4.81 | 5.13 | 4.62 | 5.59 | 4.66 |
| Long-term Debt | — | 5.68 | — | — | — |
| Long-term Lease Liabilities | 1.47 | 1.26 | 1.43 | 1.65 | 1.85 |
| Other Liabilities | 4.56 | — | 8.08 | 10.07 | 11.85 |
| Total Liabilities | 10.83 | 12.20 | 14.12 | 17.31 | 18.36 |
| Retained Earnings | (550.36) | (539.42) | (514.01) | (487.09) | (454.90) |
| Total Equity | 6.87 | 15.96 | 12.87 | 13.21 | 32.16 |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Net Income | 5.47 | 5.47 | 44.72 | (32.96) |
| D&A | — | 0.96 | 0.96 | 0.96 |
| Stock-Based Comp | — | 0.44 | 0.44 | 0.07 |
| Δ Working Cap & Other | — | (10.90) | (50.79) | 27.98 |
| Operating Cash Flow | — | (4.02) | (4.67) | (3.94) |
| CapEx | — | 0.00 | (0.01) | 0.00 |
| Investing Cash Flow | — | 0.00 | (0.01) | 0.00 |
| Stock Issuance | — | 0.00 | 15.73 | 5.00 |
| Other Financing | — | (0.65) | (1.89) | (1.19) |
| Financing Cash Flow | — | (0.65) | 13.84 | 3.81 |
| Free Cash Flow | — | (4.02) | (4.68) | (3.94) |
| LTM | 9/30/25 | 9/30/24 | 9/30/23 | 9/30/22 | |
|---|---|---|---|---|---|
| Net Income | 22.70 | 25.41 | 26.92 | (32.19) | (36.70) |
| D&A | — | 2.06 | 2.13 | 2.11 | 1.98 |
| Stock-Based Comp | — | 1.91 | 4.27 | 6.29 | 11.39 |
| Δ Working Cap & Other | — | (46.50) | (52.14) | 0.95 | 5.09 |
| Operating Cash Flow | — | (17.12) | (18.81) | (22.85) | (18.24) |
| CapEx | — | (0.04) | (0.09) | (0.36) | (0.64) |
| Other Investing | — | — | — | — | 6.13 |
| Investing Cash Flow | — | (0.04) | (0.11) | (0.37) | 5.49 |
| Stock Issuance | — | 28.29 | 23.57 | 6.55 | — |
| Other Financing | — | (4.92) | (4.06) | (1.86) | (0.64) |
| Financing Cash Flow | — | 23.37 | 19.51 | 4.69 | (0.64) |
| Free Cash Flow | — | (17.16) | (18.91) | (23.21) | (18.88) |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Current Ratio | 0.60 | 1.39 | 2.26 | 0.47 |
| Quick Ratio | — | — | — | — |
| Debt / Equity | 1.58 | 1.06 | 0.76 | 1.89 |
| EBITDA Margin % | — | — | — | — |
| Working Capital | (1.91) | 1.99 | 6.47 | (2.99) |
| Net Debt | — | — | (5.27) | — |
| ROE % | 79.5% | 49.1% | 280.3% | (469.1%) |
| ROA % | 30.9% | 23.9% | 158.8% | (162.1%) |
| LTM | 9/30/25 | 9/30/24 | 9/30/23 | 9/30/22 | |
|---|---|---|---|---|---|
| Current Ratio | 0.60 | 2.26 | 1.31 | 1.24 | 5.45 |
| Quick Ratio | — | — | 1.09 | 0.84 | 5.02 |
| Debt / Equity | 1.58 | 0.76 | 1.10 | 1.31 | 0.57 |
| EBITDA Margin % | — | — | — | — | — |
| Working Capital | (1.91) | 6.47 | 1.44 | 1.33 | 20.77 |
| Net Debt | — | (5.27) | — | — | — |
| ROE % | 330.2% | 159.2% | 209.2% | (243.6%) | (114.1%) |
| ROA % | 128.2% | 90.3% | 99.7% | (105.5%) | (72.6%) |
Insider activity (last 2 years)
| Date Filed | Reporter | Relationship | Trans. Date | Code | Shares | Price | Total Value |
|---|---|---|---|---|---|---|---|
| 2026-05-18 | KERSTEN GEERT R | Director, Officer (Chief Executive Officer) | 2026-05-14 | P | 300,000 | $1.20 | $360,000 |
| 2026-05-14 | KERSTEN GEERT R | Director, Officer (Chief Executive Officer) | 2026-05-13 | P | 100,000 | $1.19 | $119,000 |
| 2026-04-01 | TALOR EYAL | Officer (Chief Scientific Officer) | 2026-03-31 | A | 747 | $3.21 | $2,398 |
| 2026-04-01 | PRICHEP PATRICIA B | Officer (Chief Financial Officer) | 2026-03-31 | A | 1,336 | $3.21 | $4,289 |
| 2026-04-01 | KERSTEN GEERT R | Director, Officer (Chief Executive Officer) | 2026-03-31 | A | 1,682 | $3.21 | $5,399 |
| 2026-01-26 | KERSTEN GEERT R | Director, Officer (Chief Executive Officer) | 2026-01-22 | P | 38,023 | $5.26 | $200,001 |
| 2026-01-05 | TALOR EYAL | Officer (Chief Scientific Officer) | 2025-12-31 | A | 456 | $5.26 | $2,399 |
| 2026-01-05 | PRICHEP PATRICIA B | Officer (Chief Financial Officer) | 2025-12-31 | A | 815 | $5.26 | $4,287 |
| 2026-01-05 | KERSTEN GEERT R | Director, Officer (Chief Executive Officer) | 2025-12-31 | A | 998 | $5.26 | $5,249 |
| 2025-12-05 | KERSTEN GEERT R | Director, Officer (Chief Executive Officer) | 2025-12-04 | P | 8,389 | $5.96 | $49,998 |
| 2025-10-02 | TALOR EYAL | Officer (Chief Scientific Officer) | 2025-09-30 | A | 260 | $9.20 | $2,392 |
| 2025-10-02 | PRICHEP PATRICIA B | Officer (Chief Financial Officer) | 2025-09-30 | A | 466 | $9.20 | $4,287 |
| 2025-10-02 | KERSTEN GEERT R | Director, Officer (Chief Executive Officer) | 2025-09-30 | A | 570 | $9.20 | $5,244 |
| 2025-07-29 | Watson Robert Eugene | Director | 2025-07-28 | A | 4,000 | $0.01 | $40 |
| 2025-07-29 | BAILLAVOINE BRUNO JEAN-MARIE | Director | 2025-07-28 | A | 4,000 | $0.01 | $40 |
| 2025-07-29 | CIPRIANO JOHN | Officer (Senior Vice President) | 2025-07-28 | A | 7,500 | $0.01 | $75 |
| 2025-07-29 | TALOR EYAL | Officer (Chief Scientific Officer) | 2025-07-28 | A | 15,000 | $0.01 | $150 |
| 2025-07-29 | PRICHEP PATRICIA B | Officer (Chief Financial Officer) | 2025-07-28 | A | 12,000 | $0.01 | $120 |
| 2025-07-29 | KERSTEN GEERT R | Director, Officer (Chief Executive Officer) | 2025-07-28 | A | 25,000 | $0.01 | $250 |
| 2025-07-29 | Watson Robert Eugene | Director | 2025-07-25 | P | 2,919 | $6.85 | $19,995 |
| 2025-07-28 | KERSTEN GEERT R | Director, Officer (Chief Executive Officer) | 2025-07-25 | P | 29,197 | $6.85 | $199,999 |
| 2025-07-01 | TALOR EYAL | Officer (Chief Scientific Officer) | 2025-06-30 | A | 1,048 | $2.29 | $2,400 |
| 2025-07-01 | PRICHEP PATRICIA B | Officer (Chief Financial Officer) | 2025-06-30 | A | 1,873 | $2.29 | $4,289 |
| 2025-07-01 | KERSTEN GEERT R | Director, Officer (Chief Executive Officer) | 2025-06-30 | A | 2,292 | $2.29 | $5,249 |
| 2025-04-01 | TALOR EYAL | Officer (Chief Scientific Officer) | 2025-03-31 | A | 10,416 | $0.23 | $2,400 |
| 2025-04-01 | PRICHEP PATRICIA B | Officer (Chief Financial Officer) | 2025-03-31 | A | 15,432 | $0.23 | $3,556 |
| 2025-04-01 | KERSTEN GEERT R | Director, Officer (Chief Executive Officer) | 2025-03-31 | A | 22,786 | $0.23 | $5,250 |
| 2025-01-02 | KERSTEN GEERT R | Director, Officer (CEO) | 2024-12-31 | A | 12,940 | $0.40 | $5,176 |
| 2025-01-02 | TALOR EYAL | Officer (Chief Scientific Officer) | 2024-12-31 | A | 6,001 | $0.40 | $2,400 |
| 2025-01-02 | PRICHEP PATRICIA B | Officer (Chief Financial & Operations) | 2024-12-31 | A | 10,727 | $0.40 | $4,291 |
| 2024-10-01 | TALOR EYAL | Officer (Chief Scientific Officer) | 2024-09-30 | A | 2,264 | $1.06 | $2,400 |
| 2024-10-01 | PRICHEP PATRICIA B | Officer (Sr. VP of Operations) | 2024-09-30 | A | 4,047 | $1.06 | $4,290 |
| 2024-10-01 | KERSTEN GEERT R | Director, Officer (Chief Executive Officer) | 2024-09-30 | A | 4,882 | $1.06 | $5,175 |
| 2024-07-01 | TALOR EYAL | Officer (Chief Scientific Officer) | 2024-06-28 | A | 2,068 | $1.16 | $2,399 |
| 2024-07-01 | PRICHEP PATRICIA B | Officer (Senior Vice President) | 2024-06-28 | A | 3,698 | $1.16 | $4,290 |
| 2024-07-01 | KERSTEN GEERT R | Director, Officer (Chief Executive Officer) | 2024-06-28 | A | 4,461 | $1.16 | $5,175 |